The abstract presented at ESMO by Dr Harpreet Wasan – PI of the CUP-One trial: A prospective double-blind validation of molecular classifiers in the diagnosis of Cancer of Unknown Primary and clinical outcome. CUP-ONE esmo abs
LBA16 – Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP) Background With platinum-based CTX, prognosis of patients (pts) with unfavourable CUP is poor; however, CGP may inform treatment strategies
Read more